Year 2021 / Volume 113 / Number 10
Original
Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center

691-697

DOI: 10.17235/reed.2020.7431/2020

Florencia Giraudo, Eugenia Miraglia, María Laura Garbi, Martín Yantorno, María Roxana Maradeo, Gustavo Javier Correa, Francisco Tufare,

Abstract
Background and aim: dermatological manifestations are normally found in one third of patients with inflammatory bowel disease. In this study, the prevalence, clinical characteristics, intestinal disease activity, and treatment response of neutrophilic dermatoses (pyoderma gangrenosum and Sweet´s syndrome) were determined in patients with inflammatory bowel disease. Methods: a retrospective, observational study was performed in patients with inflammatory bowel disease and neutrophilic dermatoses between March 2012 and March 2018. Results: of 444 patients analyzed, 10 complied with the inclusion criteria. Seven had pyoderma gangrenosum and three presented Sweet's syndrome; and one patient developed both pathologies. The prevalence of neutrophilic dermatoses was 2.3 % (10/444), comprising 1.6 % with pyoderma gangrenosum and 0.7 % with Sweet's syndrome. Six out of seven patients with pyoderma gangrenosum were female and had ulcerative colitis. The most frequent clinical presentation of pyoderma gangrenosum was the ulcerative subtype. Active moderate-to-severe intestinal disease was found in 71.4 % of patients. Biological therapy was prescribed to three patients with partial response to corticosteroids and persistent intestinal disease activity. This therapy was not indicated for cutaneous manifestations only. Three patients with moderate-to-severe Crohn´s disease presented classical (n = 2) and pustular (n = 1) Sweet's syndrome. A complete response was achieved in all Sweet's syndrome cases treated with corticosteroids. Biological therapy was prescribed to control intestinal disease activity. Conclusions: pyoderma gangrenosum was the most frequent cutaneous manifestation of neutrophilic dermatoses, predominantly in females with ulcerative colitis, and highly associated with intestinal disease activity. Anti-tumor necrosis factor was effective in patients with partial cutaneous and intestinal disease response.
Share Button
New comment
Comments
No comments for this article
References
1. Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis 2013;20(1):213-27.
2. Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clinic Rev Allerg Immunol 2013;45(2):202-10.
3. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21(8):1982-92.
4. Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol 2017;53(3):413-27.
5. Alavi A, French LE, Davis MD, et al. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol 2017;18:355-72.
6. Suárez-Pérez JA, Herrera-Acosta E, López-Navarro N, et al. Pioderma gangrenoso: Presentación de 15 casos y revisión de la literatura. Actas Dermosifiliogr 2012;103(2):120-6.
7. Hagen JW, Swoger JM, Grandinetti LM, et al. Cutaneous manifestations of Crohn disease. Dermatol Clin 2015;33(3):417-31.
8. Curmona MC, Chiesura VC, Garay IS, et al. Pioderma gangrenoso. Dermatol Argent 2014;20(3):164-8.
9. Su WP, Davis M, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004;43:790-800.
10. Thornton JR, Teague RH, Low-Beer TS, et al. Pyoderma gangrenosum and ulcerative colitis. Gut 1980;21(3):247-8.
11. Levitt MD, Ritchie JK, Lennard-Jones JE. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991;78:676-8.
12. Thrash B, Patel M, Shah KR, et al. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acam Dermatol 2013;68(2):211.e1-33.
13. Lois M, Pizzariello G, Olivares L, et al. Estudio retrospectivo de pacientes con pioderma gangrenoso en un período de 20 años y revisión de la literatura. Dermatol Argent 2012;18(2):24-9.
14. Agarwal AL, Andrews, JM. Systematic review: IBD‐associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013;38:563-72.
15. Campanati A, Brisigotti V, Ganzetti G, et al. Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature. JEADV 2015;29(6):1245-7.
16. Malieni D, Torre AC, Baztán MC, et al. Pioderma gangrenoso asociado a colitis ulcerosa tratado con infliximab. Dermatol Argent 2009;15(3):191-5.
17. Piqueras-García J, Sahuquillo-Torralba AJ, Torres-Navarro I, et al. Pioderma gangrenoso asociado a colitis ulcerosa con buena respuesta a Ustekinumab. Actas Dermosifiliogr 2019;110(9):776-8.
18. Liu FC, Liu NT, Huang TY. Ulcerative colitis with refractory pyoderma gangrenosum. QJM 2020;113(8):567-8.
19. Gameiro A, Pereira N, Cardoso JC, et al. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol 2015;8:285.
20. Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges 2017;15:34-40.
21. Vilches FS, Vera-Kellet C. Pioderma gangrenoso: terapias clásicas y emergentes. Med Clin (Barc) 2017;149(6):256-60.
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Giraudo F, Miraglia E, Garbi M, Yantorno M, Maradeo M, Correa G, et all. Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center . 7431/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1148 visits.
This article has been downloaded 215 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 25/07/2020

Accepted: 21/10/2020

Online First: 03/12/2020

Published: 06/10/2021

Article revision time: 84 days

Article Online First time: 131 days

Article editing time: 438 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology